Health & Fitness
Thu, October 20, 2011Wed, October 19, 2011Tue, October 18, 2011Mon, October 17, 2011Sun, October 16, 2011Sat, October 15, 2011Fri, October 14, 2011Thu, October 13, 2011Wed, October 12, 2011Tue, October 11, 2011Mon, October 10, 2011Sun, October 9, 2011Sat, October 8, 2011Fri, October 7, 2011Thu, October 6, 2011Wed, October 5, 2011Tue, October 4, 2011Mon, October 3, 2011Sun, October 2, 2011Sat, October 1, 2011Fri, September 30, 2011Thu, September 29, 2011Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
//health-fitness.news-articles.net/content/2011/ .. conference-call-on-thursday-november-3-2011.html
Published in Health and Fitness on Wednesday, October 12th 2011 at 20:41 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call... -- EAST BRUNSWICK, N.J., Oct. 12, 2011 /PRNewswire/ --
Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
EAST BRUNSWICK, N.J., Oct. 12, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: [ SVNT ]) announced today that the company will release financial results for the third quarter 2011 prior to the open of the market on Thursday, November 3, 2011.
John H. Johnson, Chief Executive Officer and President, and Kenneth J. Zuerblis, Executive Vice President and Chief Financial Officer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on November 3, 2011 to discuss these results and to answer questions.
To participate by telephone, please dial 866-393-9370 (Domestic) or 706-679-1207 (International). The conference ID number is 17722127. The live and archived webcast can be accessed on the investor relations section of the Savient website at [ www.savient.com ]. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.
A telephone replay will be available from 12:00 p.m. Eastern Time on November 3, 2011 through 12:00 a.m. Eastern Time on November 17, 2011 by dialing 855-859-2056 (Domestic), alternate number 800-585-8367 or 404-537-3406 (International) and entering conference ID number 17722127.
About Savient Pharmaceuticals, Inc.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at [ www.savient.com ].
SVNT-I
Contact: | ||
Mary Coleman | Carney Noensie | |
Savient Pharmaceuticals, Inc. | Burns McClellan | |
(732) 418-9300 | (212) 213-0006 | |
SOURCE Savient Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.savient.com ]
